Document Detail

The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
MedLine Citation:
PMID:  23067322     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Hypertension is a leading cause of cardiovascular morbidity and mortality, and uncontrolled hypertension remains common despite the availability of several classes of effective antihypertensive medications. Combination therapy with antihypertensive agents of complementary actions has been advocated in the management of hypertension to maximize efficacy and minimize side effects.
AREAS COVERED: This review summarizes the current data on the triple combination therapy of aliskiren with amlodipine and hydrochlorothiazide, and discusses the clinical use of single pill triple combination of aliskiren, amlodipine and hydrochlorothiazide in the treatment of hypertension and associated cardiovascular conditions.
EXPERT OPINION: Combination therapy with antihypertensive agents of complementary actions is more effective than monotherapy in the management of hypertension. Combining an agent in renin-angiotensin blockade with a dihydropyridine calcium channel blocker (CCB) and a thiazide diuretic has plausibility in maximizing blood pressure reduction and minimizing side effects. The combination of aliskiren with amlodipine and hydrochlorothiazide has shown effective blood pressure lowering and noteworthy tolerability. The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide offers five different formulations of escalating dosages of the three agents, allowing dosing flexibility. The decreased pill burden and simplified treatment options with the single pill triple combination provide an opportunity to improve blood pressure control through improved adherence and reduced treatment inertia.
Yonghong Huan; Raymond Townsend
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-16     Completed Date:  2013-03-05     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2409-15     Citation Subset:  IM    
University of Pennsylvania, Medicine, 1 Founders Pavilion, 3400 Spruce Street, Philadelphia, PA 19104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amides / administration & dosage*,  adverse effects
Amlodipine / administration & dosage*,  adverse effects
Antihypertensive Agents / administration & dosage*,  adverse effects
Drug Combinations
Fumarates / administration & dosage*,  adverse effects
Hydrochlorothiazide / administration & dosage*,  adverse effects
Hypertension / drug therapy*
Treatment Outcome
Reg. No./Substance:
0/Amides; 0/Antihypertensive Agents; 0/Drug Combinations; 0/Fumarates; 502FWN4Q32/aliskiren; 58-93-5/Hydrochlorothiazide; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depresse...
Next Document:  Map-invariant spectral analysis for the identification of DNA periodicities.